Niagen Bioscience Inc
NAGE | NASDAQ
$3.06
+$0.02 (+0.66%)
Sep 22, 2026, 12:42 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 28.91 | 53.10 | -20.43 | -7 | -9.35 | -14.55 |
PEG Ratio | 0.24 | -0.22 | 0.29 | 0.17 | -0.44 | 0.35 |
PS Ratio | 3.89 | 4.55 | 1.21 | 1.61 | 3.73 | 4.95 |
PB Ratio | 6.58 | 9.84 | 3.54 | 4.04 | 7.92 | 17.85 |
P/FCF Ratio | 38.31 | 37.97 | 14.48 | -7.50 | -10.23 | -27.29 |
P/OCF Ratio | 37.48 | 37.46 | 14.17 | -7.67 | -10.40 | -27.65 |
OCF/S Ratio | 10.38 | 12.16 | 8.52 | -20.95 | -35.82 | -17.89 |
Debt / Equity Ratio | 0.04 | 0.06 | 0.12 | 0.15 | 0.15 | 0.10 |
Quick Ratio | 3.83 | 3.06 | 1.70 | 1.78 | 2 | 1.25 |
Current Ratio | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 | 1.96 |
Asset Turnover | 1.22 | 1.46 | 1.52 | 1.33 | 1.17 | 1.54 |
Interest Coverage | n/a | n/a | n/a | n/a | -492.24 | -279.63 |
Return on Equity | 22.71% | 18.55% | -17.35% | -57.69% | -85.50% | -121.32% |
Return on Assets | 16.34% | 12.52% | -8.98% | -30.60% | -46.90% | -51.94% |
Return on Invested Capital | 15.61% | 14.53% | -15.98% | -50.50% | -66.40% | -88.23% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 64.28% | 61.84% | 60.76% | 59.40% | 61.51% | 59.53% |
Net Profit Margin | 13.43% | 8.58% | -5.91% | -22.96% | -40.22% | -33.62% |
Pretax Profit Margin | 14.06% | 8.89% | -5.91% | -22.96% | -40.22% | -33.62% |
Operating Profit Margin | 11.05% | 7.76% | -6.70% | -25.85% | -40.14% | -33.50% |
FCF Margin | 10.16% | 11.99% | 8.34% | -21.42% | -36.43% | -18.13% |
EBITDA Margin | 15.18% | 10.38% | -3.87% | -20.34% | -37.73% | -30.95% |
Add to Watchlist
Select watchlists to add or remove NAGE